841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTION
Steven J. Moss, Matthew A. Gregory, Mohammad Nur‐e‐Alam, Nigel Coates(Isomerase Therapeutics (United Kingdom)), Philippe Gallay(Scripps Research Institute), Timothy P. Foster(University of Florida Health), Javier García-Rivera(Scripps Research Institute), P. Leyssen, Anna E. Stanley, Johan Neyts(Rega Institute for Medical Research), D. Suthar, Barrie Wilkinson(Norwich Research Park), Steven G. Kendrew, Tony Warneck
Cited by 2
Related Papers
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
|Science|1996|4.9k
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway
|Proceedings of the National Academy of Sciences|1997|483
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase
|Cell|1995|355
Active Site Residues of Cyclophilin A Are Crucial for Its Signaling Activity via CD147
|Journal of Biological Chemistry|2002|338